Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Current Liabilities (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Total Current Liabilities data on record, last reported at $41.7 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 16.32% year-over-year to $41.7 million; the TTM value through Sep 2025 reached $41.7 million, down 16.32%, while the annual FY2024 figure was $40.1 million, 29.97% up from the prior year.
  • Total Current Liabilities reached $41.7 million in Q3 2025 per STOK's latest filing, up from $38.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $49.9 million in Q3 2024 and bottomed at $21.8 million in Q2 2023.
  • Average Total Current Liabilities over 4 years is $34.3 million, with a median of $31.5 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: dropped 21.02% in 2023, then soared 103.76% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $31.4 million in 2022, then dropped by 1.83% to $30.8 million in 2023, then increased by 29.97% to $40.1 million in 2024, then rose by 4.17% to $41.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $41.7 million in Q3 2025, $38.7 million in Q2 2025, and $44.7 million in Q1 2025.